RJA
KYNB

Raymond James & Associates’s Kyntra Bio KYNB Stock Holding History

Raymond James & Associates’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,090
Closed -$975K – 3878
2023
Q1 		$975K Sell
2,090
-29
-1% -$15.3K ﹤0.01% 2464
2022
Q4 		$849K Buy
2,119
+792
+60% +$303K ﹤0.01% 2532
2022
Q3 		$432K Sell
1,327
-56
-4% -$18K ﹤0.01% 2950
2022
Q2 		$365K Buy
1,383
+32
+2% +$8.18K ﹤0.01% 3102
2022
Q1 		$406K Sell
1,351
-68
-5% -$23.7K ﹤0.01% 3198
2021
Q4 		$500K Sell
1,419
-38
-3% -$11.8K ﹤0.01% 3086
2021
Q3 		$372K Buy
1,457
+3
+0.2% +$1.06K ﹤0.01% 3265
2021
Q2 		$968K Buy
+1,454
New +$838K ﹤0.01% 2604
2019
Q2 		– Sell
-620
Closed -$843K – 3679
2019
Q1 		$843K Buy
620
+161
+35% +$218K ﹤0.01% 2304
2018
Q4 		$531K Sell
459
-59
-11% -$66.3K ﹤0.01% 2516
2018
Q3 		$787K Sell
518
-9
-2% -$13.9K ﹤0.01% 2409
2018
Q2 		$825K Buy
527
+66
+14% +$86K ﹤0.01% 2342
2018
Q1 		$533K Buy
461
+27
+6% +$35.6K ﹤0.01% 2525
2017
Q4 		$514K Sell
434
-113
-21% -$142K ﹤0.01% 2519
2017
Q3 		$736K Buy
+547
New +$576K ﹤0.01% 2267

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's KYNB Position: Q2 2023 in Review

Raymond James & Associates sold out of Kyntra Bio (KYNB) in Q2 2023, closing a stake of 2,090 shares — an estimated $975K sold.

Raymond James & Associates first reported a position in KYNB in Q3 2017 and held it in 15 quarters. The position peaked at $975K in Q1 2023. 152 funds tracked by Wall St. Rank hold KYNB as of Q2 2023.

  • Raymond James & Associates reported no remaining Kyntra Bio position as of Q2 2023 after selling out during the quarter.
  • Raymond James & Associates sold 2,090 Kyntra Bio shares in Q2 2023, an estimated $975K.
  • Raymond James & Associates first reported a position in Kyntra Bio in Q3 2017 and held it in 15 quarters.
  • Raymond James & Associates's Kyntra Bio position peaked at $975K in Q1 2023.
  • 152 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.